A late-morning session of Wednesday’s opening day of the Precision Medicine World Conference (PMWC 2024) (Jan 24-26) in Silicon Valley featured a riveting presentation by Oxford BioDynamics on a liquid biopsy test [EpiSwitch® Prostate Screening Test (PSE)], which, when combined with the standard prostate specific antigen (PSA) screening test, can improve the accuracy of prostate cancer risk screening from 55% to 94% (seehttps://www.94percent.com/). Use of this new test, which analyzes circulating chromosome conformation signatures (CCSs) highly associated with prostate cancer, could greatly reduce the problems of high rates of false-positive results associated with use of the PSA test alone. This would give patients and their doctors greater confidence in deciding whether to move forward immediately with treatment or adopt a "monitor the situation" strategy. Those with a PSE result of low likelihood of cancer can be placed on active surveillance and retested later without being referred for an invasive and often destructive prostate biopsy. A high likelihood result would prompt a referral to a urologist for consultation. Prostate cancer is the second leading cancer among men, following skin cancer.
Login Or Register To Read Full Story